Genmab A/S (GNMSF)
USD 203.33
(0.0%)
USD 203.33
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 770 Million DKK | 28.98% |
| 2022 | 597 Million DKK | 40.47% |
| 2021 | 425 Million DKK | 33.23% |
| 2020 | 319 Million DKK | 76.24% |
| 2019 | 181 Million DKK | 0.0% |
| 2018 | - DKK | 0.0% |
| 2017 | - DKK | 0.0% |
| 2016 | - DKK | -100.0% |
| 2015 | 118 Thousand DKK | -66.76% |
| 2014 | 355 Thousand DKK | -85.71% |
| 2013 | 2.48 Million DKK | -56.1% |
| 2012 | 5.66 Million DKK | -52.22% |
| 2011 | 11.84 Million DKK | -91.14% |
| 2010 | 133.71 Million DKK | 436.11% |
| 2009 | 24.94 Million DKK | 69.69% |
| 2008 | 14.69 Million DKK | -6.18% |
| 2007 | 15.66 Million DKK | -13.95% |
| 2006 | 18.2 Million DKK | -20.97% |
| 2005 | 23.03 Million DKK | -20.58% |
| 2004 | 29 Million DKK | 20.16% |
| 2003 | 24.13 Million DKK | 75.22% |
| 2002 | 13.77 Million DKK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.01 Billion DKK | 31.17% |
| 2024 Q2 | 1.01 Billion DKK | 0.89% |
| 2023 Q2 | 803 Million DKK | -3.14% |
| 2023 Q1 | 829 Million DKK | 38.86% |
| 2023 Q4 | 770 Million DKK | -2.9% |
| 2023 FY | 770 Million DKK | 28.98% |
| 2023 Q3 | 793 Million DKK | -1.25% |
| 2022 Q2 | 634 Million DKK | 52.4% |
| 2022 Q3 | 629 Million DKK | -0.79% |
| 2022 Q4 | 597 Million DKK | -5.09% |
| 2022 Q1 | 416 Million DKK | -2.12% |
| 2022 FY | 597 Million DKK | 40.47% |
| 2021 Q1 | 378 Million DKK | 18.5% |
| 2021 Q2 | 443 Million DKK | 17.2% |
| 2021 Q3 | 437 Million DKK | -1.35% |
| 2021 Q4 | 425 Million DKK | -2.75% |
| 2021 FY | 425 Million DKK | 33.23% |
| 2020 FY | 319 Million DKK | 76.24% |
| 2020 Q1 | 174 Million DKK | -3.87% |
| 2020 Q2 | 356 Million DKK | 104.6% |
| 2020 Q3 | 337 Million DKK | -5.34% |
| 2020 Q4 | 319 Million DKK | -5.34% |
| 2019 Q3 | 188.61 Million DKK | -2.8% |
| 2019 Q4 | 181 Million DKK | -4.04% |
| 2019 FY | 181 Million DKK | 0.0% |
| 2019 Q2 | 194.04 Million DKK | -2.7% |
| 2019 Q1 | 199.42 Million DKK | 0.0% |
| 2018 Q2 | - DKK | 0.0% |
| 2018 Q1 | - DKK | 0.0% |
| 2018 FY | - DKK | 0.0% |
| 2018 Q4 | - DKK | 0.0% |
| 2018 Q3 | - DKK | 0.0% |
| 2017 FY | - DKK | 0.0% |
| 2017 Q3 | - DKK | 0.0% |
| 2017 Q4 | - DKK | 0.0% |
| 2017 Q2 | - DKK | 0.0% |
| 2017 Q1 | - DKK | 0.0% |
| 2016 Q4 | - DKK | 0.0% |
| 2016 Q3 | - DKK | 0.0% |
| 2016 Q2 | - DKK | -100.0% |
| 2016 Q1 | 59 Thousand DKK | -50.0% |
| 2016 FY | - DKK | -100.0% |
| 2015 Q2 | 237 Thousand DKK | -19.93% |
| 2015 Q1 | 296 Thousand DKK | -16.62% |
| 2015 FY | 118 Thousand DKK | -66.76% |
| 2015 Q4 | 118 Thousand DKK | -33.71% |
| 2015 Q3 | 178 Thousand DKK | -24.89% |
| 2014 Q1 | 535 Thousand DKK | -78.47% |
| 2014 Q4 | 355 Thousand DKK | -14.46% |
| 2014 Q2 | 474 Thousand DKK | -11.4% |
| 2014 Q3 | 415 Thousand DKK | -12.45% |
| 2014 FY | 355 Thousand DKK | -85.71% |
| 2013 Q2 | 4.5 Million DKK | -4.75% |
| 2013 FY | 2.48 Million DKK | -56.1% |
| 2013 Q4 | 2.48 Million DKK | -98.41% |
| 2013 Q3 | 156.7 Million DKK | 3376.95% |
| 2013 Q1 | 4.73 Million DKK | -16.4% |
| 2012 FY | 5.66 Million DKK | -52.22% |
| 2012 Q1 | 10.3 Million DKK | -12.98% |
| 2012 Q2 | 8.7 Million DKK | -15.54% |
| 2012 Q3 | 7.38 Million DKK | -15.13% |
| 2012 Q4 | 5.66 Million DKK | -23.39% |
| 2011 Q4 | 11.84 Million DKK | -11.49% |
| 2011 Q2 | 14.9 Million DKK | -9.16% |
| 2011 FY | 11.84 Million DKK | -91.14% |
| 2011 Q1 | 16.4 Million DKK | -87.73% |
| 2011 Q3 | 13.38 Million DKK | -10.2% |
| 2010 Q3 | 19.65 Million DKK | -7.94% |
| 2010 Q1 | 23.05 Million DKK | -7.56% |
| 2010 FY | 133.71 Million DKK | 436.11% |
| 2010 Q2 | 21.34 Million DKK | -7.42% |
| 2010 Q4 | 133.71 Million DKK | 580.46% |
| 2009 FY | 24.94 Million DKK | 69.69% |
| 2009 Q4 | 24.94 Million DKK | 0.0% |
| 2008 FY | 14.69 Million DKK | -6.18% |
| 2007 FY | 15.66 Million DKK | -13.95% |
| 2006 FY | 18.2 Million DKK | -20.97% |
| 2005 FY | 23.03 Million DKK | -20.58% |
| 2004 FY | 29 Million DKK | 20.16% |
| 2003 FY | 24.13 Million DKK | 75.22% |
| 2002 FY | 13.77 Million DKK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -1768.796% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -18580.447% |
| SQZ Biotechnologies Company | 27.47 Million USD | -2702.956% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -1675.298% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -2486.745% |
| Mesoblast Limited | 118.7 Million USD | -548.692% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -81100.416% |
| Genus plc | 233.1 Million USD | -230.33% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -26176.384% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -57209.405% |
| Marizyme, Inc. | 18.71 Million USD | -4013.799% |
| ContraFect Corporation | 2.88 Million USD | -26626.831% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -102566.667% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -568220.208% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -53138.601% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -33004.682% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -13508.2% |
| MultiCell Technologies, Inc. | 202.58 USD | -380096651.9% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -1239.387% |
| EV Biologics, Inc. | 1.49 Million USD | -51413.597% |
| Q BioMed Inc. | 4.1 Million USD | -18634.88% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -2226.214% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -122107.286% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -62585.155% |
| Biomind Labs Inc. | 735.54 Thousand USD | -104584.709% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | -348.862% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -5824.446% |
| Skye Bioscience, Inc. | 4.61 Million USD | -16583.762% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -86605.463% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -544000.397% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -13015.112% |
| IMV Inc. | 28.88 Million USD | -2565.845% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -2993795.564% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -33995.221% |
| GB Sciences, Inc. | 1.75 Million USD | -43667.233% |
| Alpha Cognition Inc. | 1.22 Million USD | -62995.515% |
| HST Global, Inc. | 98.31 Thousand USD | -783065.004% |
| CSL Limited | 12.18 Billion USD | 93.68% |
| Halberd Corporation | 150 Thousand USD | -513233.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -77183.01% |
| Resverlogix Corp. | 6.49 Million USD | -11762.579% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -161156.545% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -301161.385% |
| argenx SE | 20 Million USD | -3750.0% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -1590.079% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -28326.889% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -7530462.347% |
| Genscript Biotech Corporation | 417.73 Million USD | -84.326% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -383717.841% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -32013.788% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -335717.804% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -1038.332% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -25344.527% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -213961.327% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -3687.879% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -517881.353% |
| BioStem Technologies, Inc. | 4.71 Million USD | -16243.278% |
| ONE Bio Corp. | 19.71 Million USD | -3805.651% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -307675.939% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -309485.076% |
| Agentix Corp. | 50 Thousand USD | -1539900.0% |
| LadRx Corporation | 33.6 Thousand USD | -2291157.514% |
| Cell Source, Inc. | 9.25 Million USD | -8220.57% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -101724.375% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -101724.375% |
| NovAccess Global Inc. | 2.19 Million USD | -34901.909% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -10786.762% |
| Itoco Inc. | 228.37 Thousand USD | -337061.798% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -364872.153% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -15352.539% |
| Kadimastem Ltd | 891.22 Thousand USD | -86297.838% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -191514.263% |
| CytoDyn Inc. | 30.07 Million USD | -2460.181% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -158897.613% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -218745.123% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -9746.598% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -628471.429% |
| Rebus Holdings, Inc. | 310 Thousand USD | -248287.097% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -16160.911% |
| International Stem Cell Corporation | 4.17 Million USD | -18329.871% |
| Bioxytran, Inc. | 1.92 Million USD | -39900.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1233617.335% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -35206.525% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -9159.259% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -8869.132% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -49402.436% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -287213.433% |
| Neutra Corp. | 54.15 Thousand USD | -1421718.45% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -41976.503% |
| PureTech Health plc | 25.51 Million USD | -2918.188% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -62796.883% |
| IXICO plc | 472.02 Thousand USD | -163027.644% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -4867.421% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -1136.69% |
| CSL Limited | 12.18 Billion USD | 93.68% |
| Cellectis S.A. | 92.77 Million USD | -729.951% |